Smith, A.L.; Eiken, A.P.; Skupa, S.A.; Moore, D.Y.; Umeta, L.T.; Smith, L.M.; Lyden, E.R.; D’Angelo, C.R.; Kallam, A.; Vose, J.M.;
et al. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. Int. J. Mol. Sci. 2022, 23, 6712.
https://doi.org/10.3390/ijms23126712
AMA Style
Smith AL, Eiken AP, Skupa SA, Moore DY, Umeta LT, Smith LM, Lyden ER, D’Angelo CR, Kallam A, Vose JM,
et al. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 2022; 23(12):6712.
https://doi.org/10.3390/ijms23126712
Chicago/Turabian Style
Smith, Audrey L., Alexandria P. Eiken, Sydney A. Skupa, Dalia Y. Moore, Lelisse T. Umeta, Lynette M. Smith, Elizabeth R. Lyden, Christopher R. D’Angelo, Avyakta Kallam, Julie M. Vose,
and et al. 2022. "A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia" International Journal of Molecular Sciences 23, no. 12: 6712.
https://doi.org/10.3390/ijms23126712
APA Style
Smith, A. L., Eiken, A. P., Skupa, S. A., Moore, D. Y., Umeta, L. T., Smith, L. M., Lyden, E. R., D’Angelo, C. R., Kallam, A., Vose, J. M., Kutateladze, T. G., & El-Gamal, D.
(2022). A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 23(12), 6712.
https://doi.org/10.3390/ijms23126712